aTYR PHARMA INC
ATYR· Nasdaq
ATYRaTYR PHARMA INC
Filed Mar 24, 2021 · 10-K · 83 days after period end · 0001564590-21-014940
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $2.05M | — | — | — |
| Net Income | -$4.93M | -$5.97M | -$6.32M | -$11.47M |
| EPS Diluted | — | -$1.54 | -$2.92 | -$0.39 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 24, 2021 · 83 d after period end
